Proteomics and metabolomics approach in adult and pediatric glioma diagnostics.

Loading...
Thumbnail Image
Identifiers

Publication date

2022

Start date of the public exhibition period

End date of the public exhibition period

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

BBA Reviews on Cancer
Metrics
Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

The diagnosis of glioma is mainly based on imaging methods that do not distinguish between stage and subtype prior to histopathological analysis. Patients with gliomas are generally diagnosed in the symptomatic stage of the disease. Additionally, healing scar tissue may be mistakenly identified based on magnetic resonance imaging (MRI) as a false positive tumor recurrence in postoperative patients. Current knowledge of molecular alterations underlying gliomagenesis and identification of tumoral biomarkers allow for their use as discriminators of the state of the organism. Moreover, a multiomics approach provides the greatest spectrum and the ability to track physiological changes and can serve as a minimally invasive method for diagnosing asymptomatic gliomas, preceding surgery and allowing for the initiation of prophylactic treatment. It is important to create a vast biomarker library for adults and pediatric patients due to their metabolic differences. This review focuses on the most promising proteomic, metabolomic and lipidomic glioma biomarkers, their pathways, the interactions, and correlations that can be considered characteristic of tumor grade or specific subtype.

Doctoral program

Description

Keywords

Biomarkers, Glioma, Metabolomics multiomics, Proteomics

Citation